BVS

Bioventus Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-05

Figures on this page computed 2026-11-08 12:24 UTC

Last close

10.61USD

Market data, 2026-11-06

Except where said otherwise: 10-K for 2025, filed 2026-03-05

31.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-05
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-11-02
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-11-02
The filing itself
4.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
12.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
1.69Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-11-02
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.36 against 0.58 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.37x

-0.72x

2.35x

0.95x

1.22x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-05

Sales1.37x
Its own average over 10 years, 414.4M.
Profit-0.72x
Its own average over 10 years, -31.7M.
Free cash flow2.35x
Its own average over 8 years, 30.6M.
Debt0.95x
Its own average over 7 years, 328.5M.
Price1.22x
Its own average over 6 years, 9. Market data, 2026-11-06

Profit is furthest from its own average, at -0.72 times.

Sales is 1.37 times its own 10-year average; Profit is -0.72 times its own 10-year average; Free cash flow is 2.35 times its own 8-year average; Debt is 0.95 times its own 7-year average; Price is 1.22 times its own 6-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-05

Sales against its own 10-year average1.37
Source
filed
Statement
income
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
The filing itself
Profit against its own 10-year average-0.72
Source
filed
Statement
income
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
The filing itself
Free cash flow against its own 8-year average2.35
Source
filed
Statement
income
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
The filing itself
Debt against its own 7-year average0.95
Source
filed
Statement
income
Fiscal year
2025
Accession
0001665988-26-000011
Reported in
USD
The filing itself
Price against its own 6-year average1.22Market data, 2026-11-06
Source
market
Taken on
2026-11-06
Reported in
USD